Home › NCT07385313
Combined OFM and Vacuum-assisted Therapy for Expedited Regeneration Over Structures
RecruitingPhase 4
Randomized Prospective Evaluation of Ovine Forestomach Matrix (OFM) and NPWT to Accelerate Tissue Coverage Over Exposed Structures
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients will be considered eligible for the study based on the following criteria: * Willing and able to provide written informed consent and to comply with the requirements of the Clinical Investigational Plan * Male or female patients aged 18 years or above * Patient is requiring reconstruction of a full thickness soft tissue defect, that includes exposed structures (bone, tendon, or neurovascular), upper or lower extremity. * Total defect size, range 25 to 800 cm2 Exclusion Criteria: * Patients will be excluded from the study based on the following criteria: * Patients with known sensitivity to ovine (sheep) derived material * Pregnant or lactating females. * Patients who are prisoners. * Patients who are likely not to complete the study. * Patients who, in the opinion of the Investigator, are unlikely to comply with the protocol. * Patients currently participating in or have participated in another clinical study within the past 30 days prior to enrolment that at the discretion of the Investigator makes them unsuitable for inclusion in the study. * Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study. * Any medical condition, recent treatment or serious intercurrent illness that, in the opinion of the Investigator, may make it undesirable for the patient to participate in the study. * Obesity (BMI\>45) * Blood glucose ≥350 mg/dL at admission * History of chronic peripheral vascular disease * Current immunosuppression * Recent neoadjuvant chemotherapy or radiotherapy * Previous or concurrent application of a cell/tissue-based product (CTP, or skin substitute) at the wound site within 30 days of the Screening Visit * Defect is a third degree burn
About the study
Demonstrate faster tissue coverage of exposed structures using OFM in combination with negative pressure wound therapy (NPWT), versus NPWT alone
What is being tested
- Myriad™ applied in conjunction with NPWT (device)
- NPWT Alone (device)
Sponsor: Aroa Biosurgery Limited · Participants: 30 · Started: Mar 31, 2026
Contact the study team
- Lizette Villarreal, MA · Phone: 2107182308
- Serina Zorilla, MSN · Phone: 7039300041
Official record on ClinicalTrials.gov — NCT07385313
Locations in the U.S.
| Colorado | University of Colorado-Anschutz Medical Campus, Aurora |
| Texas | The University of Texas Health Science Center at San Antonio, San Antonio |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.